

https://dspace.org/

Familial Hypercholesterolaemia: three decades of advances in therapy

Raal, Frederick Johan

2022

https://hdl.handle.net/10539/34198

Downloaded from a DSpace repository. https://dspace.org/

FAMILIAL HYPERCHOLESTEROLAEMIA
– THREE DECADES OF ADVANCES IN THERAPY

Frederick Johan Raal

Original published work submitted to the Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa in fulfilment of the requirements for the Degree
of
Doctor of Science in Medicine

Johannesburg, 2021

PREFACE

In this thesis original published works are presented in fulfillment of the requirements for the degree of Doctor of Science in Medicine, of the University of the Witwatersrand. All papers have been published in peer-reviewed journals which are fully indexed internationally.

1. Organizational Methodology

The thesis is written according to the "Style Guide for Theses, Dissertations and Research Reports" of the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. All references are cited in the Vancouver style. In the introduction to the thesis all publications included in the thesis are listed. However, for ease of reference, in the main body of the thesis the candidate's published works are grouped together in themes and topics for each chapter, and are appended at the end of each chapter.

2. Prizes and Awards

A number of the publications have been presented in abstract form at both local and international congresses and several have been awarded prizes. The details of the awards are as follows:

a. **Publication 3** (Paiker JE, Raal FJ, Waisberg R, Buthelezi EP. Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolaemia - which is more important? Clinica Chimica Acta 2001;314:167-173) and **publication 26** (Raal FJ, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM and Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal

antibody to proprotein convertase subtilisin/kexin type 9 serine protease, in patients with heterozygous familial hypercholesterolemia. The reduction of LDL-C with PSCK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-2417) were both awarded the AstraZeneca publication award for the best papers published in the field of Lipidology in South Africa in 2002 and 2013, respectively.

b. A poster presentation of **publication 35** (Raal FJ, Honarpour N, Blom D, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): Results of a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50) was awarded the Best Poster Award at the 82nd European Atherosclerosis Society Congress, May 31st - 3rd June, 2014, Madrid, Spain.

c. An abstract of **publication 50** (Ginsberg HN, Tuomilehto, Hovingh GK, Cariou B, Santos RD, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular Drugs and Therapy. 2019;33:69-76) was awarded a certificate, by the American College of Cardiology at the ACC meeting held in Chicago in April 2016, for the highest ranking abstract submitted from South Africa.

d. **Publication 55** (Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med

2020;382:1520-1530) was awarded Paper of the Year for 2020, late discovery category, by the Oligonucleotide Therapeutics Society.

e. An abstract of **publication 62** (Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan K-C, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383:711-720) was awarded the Paul Dudley White International Scholar Award for the highest ranked abstract from South Africa, at the American Heart Association Scientific Sessions 2020.

DECLARATION

I, Frederick Johan Raal, do hereby declare that the published works submitted by me for the degree of Doctor of Science in Medicine represent work carried out by me or in which I have actively participated. This thesis is a collection of my publications over the past three decades related to the diagnosis, management and advances in therapy of familial hypercholesterolaemia. Overall, there are 113 publications included in this thesis, of which I am either first or senior author (First author 32; Senior author 27).
For publications in which I am not first author, I have received permission from the primary author to use the publication for the purpose of this thesis.

The publications in this thesis include:

1. Work carried out largely by me, in which I contributed substantially to the design of the studies, evaluation of the results and preparation of the manuscripts, together with collaborators (publications 5,7,12,15,17,18,21,22,23,26,27,34,35,41,50,52,53,55,59, 62,73,79,81,82,84,87,94,97,102,110,111,112).

2. Work that was shared equally with collaborators (publications 1,2,3,8,9,10,11,13,16, 19,20,24,25,28,29,30,31,32,33,36,37,38,39,40,42,43,44,45,46,47,48,49,51,54,56, 57,58,60,61,63,64,65,66,67,68,69,70,71,72,74,77,78,80,83,85,86,88,89,90,91,92, 93,95,96,98,99,100,101,103,104,105,106,107,108,109,113).

3. Work carried out by higher degree candidates. My contribution was to help plan the projects and to assist with evaluation of results and preparation of the findings for publication. This work was included in three MMed degrees (publications 4,6 and 14) and two PhDs (publications 75 and 76) all at the University of the Witwatersrand.

4. All the work represented in this thesis was carried out in the Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

_____

Frederick Johan Raal

DEDICATION

To my wonderful family, my wife Anne and two children Philippa and Nicholas, for their never-ending support, love and understanding throughout my career and life.

ABSTRACT

Severe familial hypercholesterolaemia (FH), particularly homozygous FH (HoFH), remains a difficult condition to treat. As a result of markedly elevated low density lipoprotein-cholesterol (LDL-C) levels from conception, subjects with severe FH suffer from accelerated, premature atherosclerotic cardiovascular disease often resulting in premature death. However, there have been remarkable advances in treatment for this condition and this thesis describes the advances in therapy for FH over the past three decades. Lipid lowering therapies which act mainly by up regulating LDL receptor (LDLR) function, such as high intensity statin, ezetimibe and PCSK9-inhibitors, form the backbone of treatment. This combination is often sufficient to attain LDL-C targets in the majority of subject with heterozygous FH (HeFH). However, a small percentage of HeFH and the vast majority of HoFH patients are unable to achieve acceptable LDL-C levels even with this combination therapy. The addition of therapies that are independent of LDLR function, such as lomitapide and, more recently, the ANGPTL3 inhibitor, evinacumab, are required. These therapies have reduced the need for lipoprotein apheresis which is now only required for the most severe cases, particularly for those HoFH patients with minimal or no residual LDLR function. Prospects for gene therapy are promising. However, despite substantial progress, several technical issues still need to be resolved before this therapy can be safely and effectively applied.

Overcoming the challenges of severe FH has been a long and difficult journey, but with the treatment options now available, the future for severe FH looks bright.

ACKNOWLEDGEMENTS

I hereby wish to acknowledge:

- My research staff and both local, national, and international collaborators who I have had the pleasure of dealing with throughout my academic career.

- Most especially my patients, particularly my patients with homozygous familial hypercholesterolaemia, who have participated willingly in multiple studies over the years. It has been a wonderful experience for me to observe my FH patients, many of whom I have treated from a very young age and for over 30 years, mature and grow up. It has been very rewarding to observe their gratitude and their joy as their LDL-cholesterol levels have been lowered further and further with novel therapies.

- The staff of the Faculty of Health Sciences at the University of the Witwatersrand who have encouraged and supported my research over three decades.

ABBREVIATIONS

ACAT	Acyl-coA cholesterol acyltransferase
ANGPTL3	Angiopoietin-like protein 3
apoB	apolipoprotein B
ASCVD	Atherosclerotic cardiovascular disease
CETP	Cholesteryl ester transfer protein
CRP	C-reactive protein
EAS	European Atherosclerosis Society
ESC	European Society of Cardiology
FH	Familial hypercholesterolaemia
HDL-C	High-density lipoprotein cholesterol
HeFH	Heterozygous familial hypercholesterolaemia
HoFH	Homozygous familial hypercholesterolaemia
LASSA	Lipid and Atherosclerosis Society of Southern Africa
LDL-C	Low density lipoprotein cholesterol
Lp(a)	Lipoprotein(a)
LLRx	Lipid lowering therapy
LDLR	Low density lipoprotein receptor
mAb	monoclonal antibody
PCSK9	Proprotein convertase subtilisin kexin 9
siRNA	small interfering ribonucleic acid
T-C	Total cholesterol
VLDL	Very low density lipoprotein

LIST OF PUBLICATIONS INCLUDED IN THIS THESIS

1. Paiker JE, Raal FJ, von Arb M. Auto-antibodies against oxidised LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem 2000;37:174-178.
2. Paiker J, Raal FJ, Veller M, von Arb M, Chetty N, Naran NH. Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia? Clin Chimica Acta 2000;293:105-113.
3. Paiker JE, Raal FJ, Waisberg R, Buthelezi EP. Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolaemia –which is more important? Clinica Chimica Acta 2001;314:167-173.
4. Zamparini J, Immelman AR, Raal FJ. Fibroblast Growth Factor-23 in patients with homozygous familial hypercholesterolaemia. J Clin Lipidology 2018;12:767-772.
5. **Raal FJ**, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein-B and low density lipoprotein receptor gene defects. Atherosclerosis 1997;129:97-102.
6. Brown SL, Raal FJ, Panz VR, Stevens BA,Veller MG. High dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J South Afr 2004;15:70-75.
7. **Raal FJ.** A single centre retrospective observational study to evaluate the change in total cholesterol and LDL-cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J South Afr 2004;15:118-123.
8. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Watkins C, Palmer M, Wilpshaar W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008;197:400-406.
9. Panz V, Immelman A, Paiker J, Pilcher G and Raal FJ. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metabolic Syndrome and Related Disorders 2012;10:1-7.

10. Stein EA, Dann EJ, Weigman A, Skovby F, Gaudet D, Sokal E, Charng M-J, Mohamed M, Luirink I, Raichlen JS, Sunden M, Carlsson SC, Raal FJ, Kastelein JJP. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J Am Coll Cardiol 2017;70:1162-70.
11. Ballantyne CM, Houri J, Notarbartolo A for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia. Circulation 2003;107:2409-2415.
12. **Raal FJ**, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr 2007;18:325-329.
13. Stein EA, Marais AD, Szamosi T, Raal FJ, et al. Colesevelam hydrochloride: Efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatric 2010;156:231-6.
14. Botha TC, Pilcher GJ, Wolmarans K, Blom DJ, Raal FJ. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia – a retrospective review of 39 pregnancies. Atherosclerosis 2018;277:502-507.
15. **Raal FJ**, Marais AD, Lovalvo J, Klepack E, McLain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003;171:273-279.
16. Kastelein JJP, van Leuven SI, Burgess L, for the Radiance Investigators. Effect of Torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-1630.
17. **Raal FJ**, Blom DJ. Anacetrapib in familial hypercholesterolaemia. Weighing up the pros and cons. Lancet 2015;385:2124-6.
18. **Raal FJ**, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of lower LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010:375:998-1006.
19. Santos R, Raal FJ, Donovan J and Cromwell W. Mipomersen preferentially reduces small LDL particle number in patients with hypercholesterolemia. Journal of Clinical Lipidology 2015;9:201-9.

20. Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces Lipoprotein(a) in various populations with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2015;35:689-99.
21. **Raal FJ,** Stein EA. The effects of mipomersen on inhibiting hepatic VLDL apolipoprotein B100 synthesis and propensity for hepatic steatosis. Clinical Chemistry 2016;62(8):1052-1053.
22. **Raal FJ**, Braamskamp MJ, Selvey SI, Sensinger MA, Kastelein JJ. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clinical Lipidology 2016;10:860-869.
23. **Raal FJ**. Lomitapide for homozygous familial hypercholesterolaemia. Editorial Lancet 2013;381:7-8.
24. Leipold R, Raal FJ, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol 2017;24(17):1843-1850.
25. Blom DJ, Raal F, Santos RD, Marais AD. Lomitapide and mipomersen- inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. Current Atherosclerosis Reports 2019;21:481-10. DOI: 10.1007/s11883-019-0809-3.
26. **Raal FJ**, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM and Stein EA. Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients with Heterozygous Familial Hypercholesterolemia. The reduction of LDL-C with PSCK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation 2012;126:2408-2417.
27. **Raal FJ**, Panz V, Immelman A and Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013;2:e000028 doi: 10.1161/JAHA.112.000028.
28. Stein EA and Raal FJ. Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: Of Mice and Man. Editorial Circulation 2013;127:2372-2374.
29. Blom DJ, Marais AD, Raal FJ, Lambert G. The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clin Lipidol 2013;8(2):243-256.

30. Stein EA, Wasserman SM, Dias C, Scott R and Raal FJ. AMG-145. Drugs of the Future 2013;38(7):451-459.
31. Stein EA, Honarpour N, Wasserman SM, Zu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-2120.
32. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman S and Sabatine M. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients with hypercholesterolemia. 52-Week Results from the open-label study of long-term evaluation against LDL-C (OSLER) Randomized Trial. Circulation 2014;129:234-243.
33. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R and Sabatine M. Efficacy and safety of evolocumab (AMG) 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal 2014;35:2249-59.
34. **Raal FJ**, Stein EA, Dufour R, Turner T, Civeira F, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): Results of a randomised double-blind, placebo controlled trial. Lancet 2015;385:331-340.
35. **Raal FJ**, Honarpour N, Blom D, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): Results of a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50.
36. Sabatine MS, Giugliano RP, Wiviott SS, Raal FJ, et al. Efficacy and safety of Evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9.
37. Robinson JG, Farnier MD, Krempf M, Raal FJ, et al. Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99.
38. Stein EA, Raal FJ. Update on PCSK9 inhibitors and new therapies. US Endocrinology 2016;12(1):18-21.

39. Thedrez A, Sjouke B, Passard M, Raal F, et al. Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2016;36:1647-1650.
40. Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E. Efficacy and safety of Alirocumab in patients with heterozygous familial hypercholesterolaemia and LDL-C of 160mg/dl or higher. Cardiovasc Drugs Ther 2016;30:473-483.
41. **Raal FJ**, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA. Long-term treatment with evolocumab added to maximal drug therapy with or without apheresis in patients with homozygous familial hypercholesterolemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes and Endocrinol 2017;5:280-290.
42. Koren MK, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratane R, Raal FJ. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia. Results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017;2(6): 598-607.
43. Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Long-term safety, tolerability and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia. J Clin Lipidology 2017;11:1448-1457.
44. Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): Implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol 2018;38:592-598.
45. Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A. Efficacy, safety and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT Trial. J Clin Lipidol 2018;12:1199-1207.

46. Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies. Clinical Cardiology 2018;41:1328-1335.
47. Ginsberg HN, Tuomilehto, Hovingh GK, Cariou B, Santos RD, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular Drugs and Therapy. 2019;33:69-76. DOI 10.1007/s10557-019-06852-6.
48. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. Final report of the OSLER-1 Study: Long-term evolocumab treatment of hypercholesterolemia. JACC 2019;74:2132-46. DOI 10.1016/j.jacc.2019.08.1024.
49. Blom DJ, Breedt J, Burgess L, Iftikhar OE, Ellis G, Soma P, van der Walt E, Naidoo P, van Tonder A, Raal FJ. Long term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia – the ODYSSEY open label extension study. Cardiovasc J Afr 2019;30:279-284. DOI: 10.5830/CVJA-2019-039.
50. **Raal FJ**, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos RD, Ferdinand KC, Wright RS, Navarese EP, Lerch DM, Louie MJ, Lee LV, Letierce A, Robinson JG. Treatment effect of alirocumab according to age group, smoking status and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. J Clin Lipidol 2019;13:735-743. DOI: 10.1016/j.jacl.019.06.006.
51. Santos RD, Stein EA, Hovingh GK, Raal FJ, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol 2020;75:565-74. DOI: 10.1016/j.jacc2019.12.020.
52. **Raal FJ**, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman S, Huang F, Xue A, Albizem M, Scott R and Stein EA. Reduction in Lipoprotein(a) with PCSK9 Monoclonal Antibody Evolocumab (AMG 145). A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol 2014;63:1278-88.
53. **Raal FJ**, Guigliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Lipid Res 2016;57:1086-1096.

54. Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ. Effect of alirocumab on lipoprotein(a) over ≥ 1.5 years (from the Phase 3 ODYSSEY program). Am J Cardiol 2017;119:40-46.
55. **Raal FJ**, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020;382:1520-1530. DOI:10.1056/NEJMoa1913805.
56. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros MJ, Wijngaard PLJ, Kastelein JJP. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-1519. DOI:10.1056/NEJMoa12387.
57. Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 in homozygous familial hypercholesterolemia. The ORION-2 pilot study. Circulation 2020;141:1829-1831. DOI: 10.1161/CIRCULATIONAHA.119.044431.
58. Marais AD, Blom DJ, Raal FJ. Homozygous familial hypercholesterolemia and its treatment with inclisiran. Expert Opinion on Orphan Drugs. 2020;8(6):197-208. DOI:10.1080/21678707.2020.1784721.
59. **Raal FJ**, Chilton R, Ranjith N, et al. PCSK9 inhibitors: From nature's lessons to clinical utility. Endocrine, Metabolic & Immune Disorders – Drug Targets 2020;20:840-854. DOI: 10.2174/1871530320666200213114138.
60. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz G, Friedman A, Wijngaard PLJ, Conde LG, Kastelein JJP. Pooled patient-level analysis of Inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis . J Am Coll Cardiol 2021;77:1182-93. DOI:10.1016/j.jacc.2020.12.058.
61. Brandts J, Dharmayat KI, Vallejo-Vaz AJ, Sharabiani MTA, Jones R, Kastelein JJP, Raal FJ. Ray KK. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis 2021;325:46-56. DOI:10.1016/j.atherosclerosis.2021.03.042.

62. **Raal FJ**, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan K-C, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383:711-720. DOI: 10.1056/NEJMoa2004215.
63. Mohammed F, Seedat F, Raal FJ. Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes 2021;28:188-195.
64. Mohamed F, Botha TC, Raal FJ. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol 2021;32:213-218.
65. Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, Van der Westhuyzen DR. Characterization of six patients who are double heterozygotes for familial hypercholesterolaemia and familial defective apo B-100. Arteriosclerosis and Thrombosis 1993;**13**:1076-1081.
66. Kotze MJ, Loubser O, Thiart R, de Villiers JNP, Langenhoven E, Theart L, Steyn K, Marais AD, Raal FJ. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet 1997;51:394-398.
67. Kotze MJ, de Villiers JNP, Loubser O, Thiart R, Scholtz CL, Raal FJ. A double mutant LDL receptor allele in a Cypriot family with heterozygous familial hypercholesterolaemia. Hum Genet 1997;100:101-103.
68. Thiart R, Loubser O, de Villiers JNP, Marx MP, Zaire R, Raal FJ, Kotze MJ. Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolaemia. Human Mutation 1998;1:S232-S233.
69. Callis M, Jansen S, Thiart R, de Villiers JN, Raal FJ, Kotze MJ. Mutation analysis in familial hypercholesterolaemia patients of different ancestries: identification of three novel LDLR gene mutations. Mol Cell Probes 1998;12:149-152.
70. Kotze MJ, Peeters AV, Loubser O, Theart L, du Plessis L, Hayes VM, de Jong G, de Villiers JN, Lombard CJ, Hansen PS, Raal FJ. Familial hypercholesterolaemia: potential diagnostic value of mutation screening in a paediatric population of South Africa. Clin Genet 1998;54:74-78.
71. Durst R, Colombo R, Shpitzen S, Avi LB, Raal FJ. Recent origin and spread of a common Lithuanian mutation, G197delLDLR, causing familial hypercholesterolemia: Positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. Am J Hum Genet 2001;68:1172-1188.

72. Marais AD, Kotze MJ, Raal FJ, Khine AA, Urban M, Talmud P, Humphries SE. Familial hypercholesterolaemia workshop for leveraging point of care testing and personalized medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc J Afr 2019;30:297-304. DOI: 10.5830/CVJA-2019-055.
73. **Raal FJ**, Bahassi EM, Turner TA, Stevens B. Stein EA. Cascade screening for Familial Hypercholesterolemia in South Africa: The Wits Find-FH Program. Atheroscler Thromb Vasc Biol 2020;40:2747-2755. DOI:10.1161/ATVBAHA.120.315040.
74. Ibe UK, Whittal R, Humphries SE, Pilcher G, Raal FJ. Analysis of mutations causing familial hypercholesterolaemia in native South African patients of different ancestry. S Afr Med J 2017;107:145-148.
75. Smyth N, Ramsay M, Raal FJ. Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. Curr Opin Lipidol 2018;29:72-79.
76. Hayat M, Kerr R, Bentley R, Rotimi CN, Raal FJ, Ramsay M. Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLOS One 15(2): e0229098. DOI: 10.1371/journal.pone.0229098.
77. Kraft H-G, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:522-528.
78. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemias in South Africa – Clinical Guideline 2000. S Afr Med J 2000;90:164-178.
79. **Raal FJ**, Schamroth C, Klug E, Mills P. The South African Lipid Guidelines – Is there a need for an update? Cardiovasc J South Afr 2004;15:53-54.
80. Marais AD, Blom DJ, Raal FJ. Familial hypercholesterolaemia in South Africa: A reminder. S Afr Med J 2021;111:700-701 DOI:10.7196/SAMJ.2021.v111i8.15782.
81. **Raal FJ**, Marais AD, Schamroth C. Adoption of the European guidelines on cardiovascular disease prevention in clinical practice (based on De Baker et al. European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610) – Guide to lipid management. SA Heart, Suppl. July 2006; 12-16.

82. **Raal FJ**. Hypercholesterolaemia in children and young adults; current management. SA Fam Pract 2008;50(1):10-13.
83. Ramjeeth A, Butkow N, Raal F, Maholwana-Mokgatlhe M. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: The South African Not At Goal study (SA-NAG). Cardiovasc J Afr 2008:19:88-94.
84. **Raal F**, Schamroth C, Blom D et al. CEPHEUS SA: A South African survey on the under-treatment of hypercholesterolaemia. Cardiovasc J Afr 2011;22:234-240.
85. South African Dyslipidaemia Guideline Consensus Statement. A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J 2012;102:177-188.
86. Klug EQ, Raal FJ, Marais AD, Taskinen M-R, Dalby AJ, Schamroth C, Rappaport N, Jankelow D, Blom DJ, Catsicas R, Webb DA. South African Dyslipidaemia Guideline Consensus Statement. S Afr Fam Pract 2013;55(1):9-18.
87. **Raal FJ**, Blom DJ, Naidoo S, Bramlage P, Brudi P. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovasc J Afr 2013;24(8):330-338.
88. Klug EQ, Raal FJ. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J 2020;110(11)1059. DOI:10.7196/SAMJ.2020.v110i11.1519.
89. Chiang C, Ferrieres J, Gotcheva NN, Raal FJ, Shehab A, Sung J, Henriksson KM, Hermans MP. Suboptimal control of lipid levels: Results from 29 countries participating in the Centralized Pan-Regional Surveys on the Under treatment of Hypercholesterolemia (CEPHEUS). Journal of Atherosclerosis and Thrombosis 2016;23:567-587.
90. Klug E, Raal FJ, Marais AD, Smuts CM, Schamroth C, Jankelow D, Blom DJ, Webb DA. South African Dyslipidaemia Guideline Consensus Statement 2018. S Afr Med J 2018;11(2):973-997.
91. Blom DJ, Ranjith N, Joshi P, Naidoo P, van Tonder A, Musa MG, Leisegang R, Trokis JS, Makan H, Raal FJ. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr 2020;31:245-251. DOI:10.5830/CVJA-2020-010.

92. Blom DJ, Raal F, Amod A, Naidoo P, Lai Y. Management of low-density lipoprotein cholesterol levels in South Africa: The International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr 2019;30:15-23. DOI: 10.5830/CVJA-2018-054.
93. Nordestgaard BG, Chapman MS, Raal FJ et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. European Heart Journal 2013;34:3478-3490.
94. **Raal FJ** and Santos RD. Homozygous familial hypercholesterolaemia: Current perspectives on diagnosis and treatment. Atherosclerosis 2012;223:262-268.
95. Stein EA, Raal FJ. Polygenic familial hypercholesterolaemia: does it matter? Editorial Lancet 2013;381:1255-57.
96. Watts GF, Gidding S, Wierzbicki AS, Toth P, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJG, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S and Kastelein JJP. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology 2014;171:309-325.
97. **Raal FJ** and Stein EA. What matters most in pediatric familial hypercholesterolemia, genotype or phenotype? Journal of Lipid Research 2014;55:947-955.
98. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts, GF, Averna M, Boileau C, Boren J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AFH, Stroes E, Taskinen M, Wiegman A, Wiklund O and Chapman MJ. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal 2014;35:2146-57.
99. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Raal FJ, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36:2425-2437.

100. Gidding SS, Champagne MA, De Ferranti SD, Raal FJ, et al. The agenda for Familial Hypercholesterolemia. A Scientific Statement from the American Heart Association. Circulation 2015;132:2167-2192.

101. Ference BA, Ginsberg HN, Graham I, Raal FJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017;38:2459-2472.

102. **Raal FJ**, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis 2018;277:483-492.

103. Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon J, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard GB, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal F, Ray KK, Schunkert H, Taskinen M-R, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-2330. DOI: 10.1093/eurheartj/ehz962.

104. Watts GF, Gidding SS, Mata P, Raal FJ, et al. Familial hypercholesterolemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol 2020;17(6):360-377. DOI:10.1038/s41569-019-0325-8.

105. Vallejo-Vaz, AJ, Seshasai SR, Cole D, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, et al. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis 2015;243:257-59.

106. The EAS Familial Hypercholesterolaemia Studies Collaboration. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS familial hypercholesterolaemia studies collaboration Atherosclerosis Suppl. 2016;22:1-32.

107. EAS Familial Hypercholesterolaemia Studies Collaboration. Overview of the current status of and initiatives related to familial hypercholesterolaemia in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018;277:234-255.

108. Vuorio A, Raal FJ, Kaste M, Kovanen PT. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment Atherosclerosis 2021;320:53-60. DOI:10.1016/j.atherosclerosis.2021.01.021.

109. Vuorio A, Raal F, Kovanen PT. Hospitalized children with familial hypercholesterolemia and COVID-19: a case for preventative anticoagulation. Frontiers in Cardiovascular Medicine 8:657719. DOI:10.3389/fcvm.2021.657719.

110. **Raal FJ**, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-2207.

111. **Raal FJ**, Sjouke B, Hovingh GK, Isaac BF. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis 2016;248:238-44.

112. **Raal FJ**, Sjouke B, Hovingh GK, Isaac BF. Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. Data in Brief 2016;7:1458-62.

113. Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. European Heart Journal 2018;39:1162-1168.

TABLE OF CONTENTS

Title page..……..… i

Preface……..……..… ii

Declarations…….… v

Dedication…….……...…….….... vi

Abstract…..…… vii

Acknowledgements……...…….……...… viii

Abbreviations…….... ix

List of Publications……... x

CHAPTER 1…INTRODUCTION…….…… **2**

CHAPTER 2…THE STATIN AND EZETIMIBE ERA……... **5**

CHAPTER 3... MIPOMERSEN, LOMITAPIDE AND SOME FAILED THERAPIES FOR SEVERE FH…… **8**

CHAPTER 4... PCSK9 INHIBITION, MONOCLONAL ANTIBODIES AND INCLISIRAN……... **10**

CHAPTER 5… ANGPTL3 INHIBITION……... **16**

CHAPTER 6… FH IN SOUTH AFRICA ……...… **17**

CHAPTER 7… LOCAL AND INTERNATIONAL FH AND LIPID GUIDELINES……..…….……. **19**

CHAPTER 8… REDUCTION IN MORTALITY IN SEVERE FH…….. **24**

CHAPTER 9… CONCLUSIONS AND PLANNED FUTURE RESEARCH…… **25**

CHAPTER 1: INTRODUCTION

My main area of research interest has been in subjects with familial hypercholesterolaemia (FH). FH is one of the most common inherited disorders in the world affecting approximately 1 in every 300 persons, or over 30 million people, worldwide. In the Afrikaner, Jewish and Indian populations of South Africa the prevalence is even higher, with about 1 in every 80 persons affected. FH is mainly caused by mutations affecting the function of the LDLR which lead to diminished clearance of cholesterol from the circulation and, consequently, to markedly elevated LDL-C levels. Less frequently FH can result from mutations in apoB or gain-of-function mutations in PCSK9. The resultant hypercholesterolaemia predisposes these patients to severe premature atherosclerosis, particularly atherosclerotic coronary artery disease. The concentration of LDL-C and lifetime vascular exposure to raised plasma LDL-C concentrations are major determinants of atherosclerosis, but there remains a considerable variability in the extent of atherosclerosis present and in the expression of atherosclerotic cardiovascular disease (ASCVD) in these patients. Other genetic or environmental factors affecting LDLR function or qualitative differences in LDL, such as LDL particle size and susceptibility to lipid oxidation, may play a role, as may other biochemical risk factors.

Initial treatment of homozygous FH (HoFH) included oral therapy with the bile-acid sequestrant cholestyramine, which was poorly tolerated and of limited efficacy. Portacaval shunt or ileal bypass surgery was also performed but these surgical procedures were shown to be of limited, if any, benefit. The role of lipid oxidation in the pathogenesis of atherosclerosis became a major focus of lipid research in the 1990s, the hypothesis being that antioxidants may slow progression or even reverse atherosclerosis. At the time, we initiated studies with probucol, a potent antioxidant, as well as with high doses of vitamin E, a fat-soluble antioxidant, in subjects with HoFH. However, antioxidants were shown to be of little benefit in this patient group.

The purpose of my PhD thesis, which I was awarded in 1999, was to determine whether such qualitative differences in LDL are important determinants of the extent and severity of atherosclerosis and to determine whether it is mainly the reduction in LDL-C that is of benefit, or whether antioxidant therapy would also be effective in preventing progression of atherosclerosis in FH subjects. FH patients, particularly patients with HoFH were found to have large, buoyant LDL particles, which are less susceptible to lipid oxidation than smaller,

denser particles. Interestingly, in the absence of other causes of insulin resistance, patients with FH have normal fasting insulin and triglyceride levels, normal postprandial lipaemia, and do not have microalbuminuria (1.1; publications 1-8). They, therefore, usually show no features of the metabolic syndrome despite severe, accelerated atherosclerosis. The conclusion of my thesis was that in subjects with FH, quantitative rather than qualitative differences in LDL are associated with accelerated atherosclerosis and that therapy in FH should therefore be aimed primarily at reducing LDL-C bulk by reducing the LDL-C level as early and as aggressively as possible (1.1; publications 5,7. 1.2; publication 1). Publications included in my PhD thesis and therefore not included in this thesis are listed below (1.1; publications 1-8). Additional publications in this area not included in my PhD thesis and forming part of this thesis are also shown (1.2; publications 1-4).

Publications

1.1 Part of PhD so referenced but not included in this thesis

1. Raal FJ, Areias AJ, Pilcher GJ, Joffe BI, Seftel HC. Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. Atherosclerosis 1994;107:213-219.
2. Areias AJ, Richardson J, Raal FJ. Rapid method for measuring copper induced LDL oxidation. Eur J Lab Med 1995;1:95-97.
3. Zouvanis M, Raal FJ, Joffe BI, Seftel HC. Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 1995;113:289-292.
4. Raal FJ, Areias AJ, Waisberg R, von Arb M. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis 1995;115:9-15.
5. Raal FJ, Areias AJ, Joffe BI. Low density lipoproteins and atherosclerosis - quantity or quality? Redox Report 1995;1:171-176.
6. Raal FJ, Panz VR, Pilcher GJ, Joffe BI. Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. J Int Med 1999;246:75-80.
7. Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol 1999;83:1330-1333.

8. Raal FJ, Pilcher GJ, Veller MG, Kotze MJ, Joffe BI. Efficacy of vitamin E compared to either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol 1999;84:1344-1346.

1.2 Additional publications in this area forming part of this thesis

1. Paiker JE, Raal FJ, Waisberg R, Buthelezi EP. Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolaemia –which is more important? Clinica Chimica Acta 2001;314:167-173.
2. Paiker JE, Raal FJ, von Arb M. Auto-antibodies against oxidised LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem 2000;37:174-178.
3. Paiker J, Raal FJ, Veller M, von Arb M, Chetty N, Naran NH. Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia? Clin Chimica Acta 2000;293:105-113.
4. Zamparini J, Immelman AR, Raal FJ. Fibroblast Growth Factor-23 in patients with homozygous familial hypercholesterolaemia. J Clin Lipidology 2018;12:767-772.

CHAPTER 2: THE STATIN AND EZETIMIBE ERA

With the arrival of statin therapy in South Africa in the late 1990s, and with the lack of efficacy of antioxidant therapy in HoFH subjects, my research focus changed. Therapy aimed primarily at reducing LDL-C levels as early and as aggressively as possible became paramount. I have shown, in collaboration with many local and international colleagues, that high dose statin therapy can reduce LDL-C levels in subjects with HoFH, even in those who are receptor negative - suggesting that high dose statin therapy must also act, at least in part, by reducing or inhibiting very low density lipoprotein (VLDL) and apolipoprotein B (apoB) production (2.1; publications 1,2. 2.2; publications 1-6). More recently another proposed mechanism has been statin induced hepatic retinoid X receptor activation with reduction in ANGPTL3 levels. Resins are poorly tolerated but the introduction of resins that were better tolerated, such as colesevelam and the cholesterol absorption inhibitor, ezetimibe, shortly after statins were introduced allowed for a further reduction in LDL-C levels even in subjects with HoFH (2.2; publications 7-9). In resource poor countries like South Africa where access to lipoprotein apheresis is not readily available or affordable, we have shown that high intensity statin plus ezetimibe therapy reintroduced in the second trimester of pregnancy once the foetus is fully formed, appears to be safe (2.2; publication 10).

2. Publications

2.1 Part of PhD so referenced but not included in this Thesis

1. Raal FJ, Pilcher GJ, Illingworth DR, Pappu AS, Stein EA, Laskarzewski P, Mitchel YB, Melino MR. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 1997;135:249-256.
2. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 2000;150:421-428.

2.2 Additional publications in this area forming part of this Thesis

1. **Raal FJ**, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein-B and low density lipoprotein receptor gene defects. Atherosclerosis 1997;129:97-102.
2. Brown SL, Raal FJ, Panz VR, Stevens BA,Veller MG. High dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J South Afr 2004;15:70-75.
3. **Raal FJ.** A single centre retrospective observational study to evaluate the change in total cholesterol and LDL-cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J South Afr 2004;15:118-123.
4. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Watkins C, Palmer M, Wilpshaar W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008;197:400-406.
5. Panz V, Immelman A, Paiker J, Pilcher G and Raal FJ. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metabolic Syndrome and Related Disorders 2012;10:1-7.
6. Stein EA, Dann EJ, Weigman A, Skovby F, Gaudet D, Sokal E, Charng M-J, Mohamed M, Luirink I, Raichlen JS, Sunden M, Carlsson SC, Raal FJ, Kastelein JJP. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J Am Coll Cardiol 2017;70:1162-70.
7. Ballantyne CM, Houri J, Notarbartolo A for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia. Circulation 2003;107:2409-2415.
8. **Raal FJ**, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr 2007;18:325-329.
9. Stein EA, Marais AD, Szamosi T, Raal FJ, et al. Colesevelam hydrochloride: Efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatric 2010;156:231-6.

10. Botha TC, Pilcher GJ, Wolmarans K, Blom DJ, Raal FJ. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia – a retrospective review of 39 pregnancies. Atherosclerosis 2018;277:502-507.

CHAPTER 3: MIPOMERSEN, LOMITAPIDE AND SOME FAILED THERAPIES FOR SEVERE FH

However, despite high-intensity statin together with ezetimibe therapy, severe FH patients, especially those with HoFH, are unable to achieve acceptable LDL-C levels. New therapies that would lower LDL-C further were needed. I was involved in studies with novel agents such as ACAT inhibitors (3; publications 1-3), CETP inhibitors, and thyromimetics in this patient group but none of these therapies stood the test of time and were discontinued because of lack of efficacy or safety reasons. I reported in the Lancet on the use of mipomersen, a novel antisense oligonucleotide directed against apoB, in HoFH subjects (3; publication 4). Twenty-six of the 51 subjects enrolled into this study were my patients. Mipomersen was shown to be effective and reduced LDL-C by a further 30% and also lowered Lp(a) levels by 25% in HoFH patients (3; publications 4-8). Unfortunately, because of side effects, this therapy has also been withdrawn from the market. Lomitapide, the microsomal triglyceride transfer protein (MTP) inhibitor, is however still an option for patients with severe HoFH but the concern is hepatic steatosis (3; publications 9-11)

3. Publications

1. **Raal FJ**, Marais AD, Lovalvo J, Klepack E, McLain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003;171:273-279.
2. Kastelein JJP, van Leuven SI, Burgess L, for the Radiance Investigators. Effect of Torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-1630.
3. **Raal FJ**, Blom DJ. Anacetrapib in familial hypercholesterolaemia. Weighing up the pros and cons. Lancet 2015;385:2124-6.
4. **Raal FJ**, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of lower LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010:375:998-1006.

5. Santos R, Raal FJ, Donovan J and Cromwell W. Mipomersen preferentially reduces small LDL particle number in patients with hypercholesterolemia. Journal of Clinical Lipidology 2015;9:201-9.
6. Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces Lipoprotein(a) in various populations with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2015;35:689-99.
7. **Raal FJ,** Stein EA. The effects of mipomersen on inhibiting hepatic VLDL apolipoprotein B100 synthesis and propensity for hepatic steatosis. Clinical Chemistry 2016;62(8):1052-1053.
8. **Raal FJ**, Braamskamp MJ, Selvey SI, Sensinger MA, Kastelein JJ. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clinical Lipidology 2016;10:860-869.
9. **Raal FJ**. Lomitapide for homozygous familial hypercholesterolaemia. Editorial Lancet 2013;381:7-8.
10. Leipold R, Raal FJ, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol 2017;24(17):1843-1850.
11. Blom DJ, Raal F, Santos RD, Marais AD. Lomitapide and mipomersen- inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. Current Atherosclerosis Reports 2019;21:481-10. DOI: 10.1007/s11883-019-0809-3.

CHAPTER 4: PCSK9 INHIBITION, MONOCLONAL ANTIBODIES AND INCLISIRAN

The management of HeFH has been revolutionized by the introduction of PCSK9-inhibitors. Together with high-intensity statin, with or without ezetimibe therapy, these agents reduce LDL-C a further 60% allowing many patients with HeFH to achieve LDL-C levels we were not able to achieve previously (4; publications 1-26). This therapy also modestly reduces Lp(a) by approximately 30% (4; publications 27-29). PCSK9-inhibitor therapy has also been shown to reduce cardiovascular events in large outcome studies in subjects with established ASCVD or at high risk for ASCVD (4; publications 11,12). As PCSK9-inhibitors act indirectly by up-regulating LDLR function it was uncertain whether these drugs would work in subjects with HoFH who may have minimal or no residual LDLR function. However, the vast majority, over 70%, of HoFH patients, identified worldwide are receptor “defective" rather than receptor negative and have some residual LDLR activity which could be upregulated by PCSK9-inhibitor therapy. I drew the attention of the pharmaceutical industry to this unmet need and approached two companies who were leading the development of PCSK9-inhibitor therapy with mAbs at the time. Amgen kindly agreed to the proposal provided I helped with the study design. Two Investigator initiated studies were performed. The first study was a proof-of-concept study in 8 HoFH subjects which demonstrated that PCSK9-inhibitor therapy is indeed effective in HoFH (4; publication 6). This was published in *Circulation* in 2013. Subsequently a much larger, double-blind, placebo-controlled study with the PCSK9-inhibitor, evolocumab, was performed. In 2015, I published two articles in the same edition of *the Lancet* on the safety and efficacy of the PCSK9 mAb inhibitor evolocumab in subjects with either HeFH (RUTHERFORD study) or HoFH (TESLA study) (4; publications 9,10). Used in combination with other lipid-lowering therapies, this therapy reduced LDL-C by a further 60% in HeFH subjects and by a further 30% in those with HoFH. In these papers, I also reported on the effect the underlying FH genotype has on response to PCSK9 mAb inhibitor therapy. The underlying genotype does not affect the response in subjects with HeFH probably because of marked upregulation of the 50% normal LDL receptors but in those with HoFH the response is determined by the underlying genotype (4, publication 9). Those HoFH patients with residual LDL receptor activity (non-null) respond well but those with minimal or no residual LDL receptor activity (null/null) respond poorly, if at all, to this therapy (4; publications 10,16,19). These two papers have been widely cited and this therapy has revolutionised the management of severe FH.

Rather than inhibiting PCSK9 with mAb therapy, inhibiting the production of PCSK9 by the liver by means of small interfering RNA (siRNA), is also a revolutionary approach (4; publications 30-36). This therapy has been shown to similarly reduce LDL-C by a further 50%. As first author I recently published the results of treatment with inclisiran, a siRNA directly against PCSK9, in subjects with HeFH, in the *New England Journal of Medicine* in 2020 (4; publication 30). A pilot study showed that inclisiran may also be effective at least in some subjects with HoFH (4; publication 32). The advantage over mAb therapy is that inclisiran only needs to be administered twice a year which will revolutionize the management of difficult-to-treat hypercholesterolaemia and guarantee compliance.

4. Publications

1. **Raal FJ**, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM and Stein EA. Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients with Heterozygous Familial Hypercholesterolemia. The reduction of LDL-C with PSCK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation 2012;126:2408-2417.
2. **Raal FJ**, Panz V, Immelman A and Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013;2:e000028 doi: 10.1161/JAHA.112.000028.
3. Stein EA and Raal FJ. Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: Of Mice and Man. Editorial Circulation 2013;127:2372-2374.
4. Blom DJ, Marais AD, Raal FJ, Lambert G. The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clin Lipidol 2013;8(2):243-256.
5. Stein EA, Wasserman SM, Dias C, Scott R and Raal FJ. AMG-145. Drugs of the Future 2013;38(7):451-459.

6. Stein EA, Honarpour N, Wasserman SM, Zu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-2120.
7. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman S and Sabatine M. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients with hypercholesterolemia. 52-Week Results from the open-label study of long-term evaluation against LDL-C (OSLER) Randomized Trial. Circulation 2014;129:234-243.
8. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R and Sabatine M. Efficacy and safety of evolocumab (AMG) 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal 2014;35:2249-59.
9. **Raal FJ**, Stein EA, Dufour R, Turner T, Civeira F, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): Results of a randomised double-blind, placebo controlled trial. Lancet 2015;385:331-340.
10. **Raal FJ**, Honarpour N, Blom D, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): Results of a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50.
11. Sabatine MS, Giugliano RP, Wiviott SS, Raal FJ, et al. Efficacy and safety of Evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9.
12. Robinson JG, Farnier MD, Krempf M, Raal FJ, et al. Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99.
13. Stein EA, Raal FJ. Update on PCSK9 inhibitors and new therapies. US Endocrinology 2016;12(1):18-21.
14. Thedrez A, Sjouke B, Passard M, Raal F, et al. Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2016;36:1647-1650.

15. Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E. Efficacy and safety of Alirocumab in patients with heterozygous familial hypercholesterolaemia and LDL-C of 160mg/dl or higher. Cardiovasc Drugs Ther 2016;30:473-483.
16. **Raal FJ**, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA. Long-term treatment with evolocumab added to maximal drug therapy with or without apheresis in patients with homozygous familial hypercholesterolemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes and Endocrinol 2017;5:280-290.
17. Koren MK, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratane R, Raal FJ. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia. Results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017;2(6): 598-607.
18. Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Long-term safety, tolerability and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia. J Clin Lipidology 2017;11:1448-1457.
19. Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): Implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol 2018;38:592-598.
20. Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A. Efficacy, safety and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT Trial. J Clin Lipidol 2018;12:1199-1207.
21. Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies. Clinical Cardiology 2018;41:1328-1335.

22. Ginsberg HN, Tuomilehto, Hovingh GK, Cariou B, Santos RD, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular Drugs and Therapy. 2019;33:69-76. DOI 10.1007/s10557-019-06852-6.
23. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. Final report of the OSLER-1 Study: Long-term evolocumab treatment of hypercholesterolemia. JACC 2019;74:2132-46. DOI 10.1016/j.jacc.2019.08.1024.
24. Blom DJ, Breedt J, Burgess L, Iftikhar OE, Ellis G, Soma P, van der Walt E, Naidoo P, van Tonder A, Raal FJ. Long term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia – the ODYSSEY open label extension study. Cardiovasc J Afr 2019;30:279-284. DOI: 10.5830/CVJA-2019-039.
25. **Raal FJ**, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos RD, Ferdinand KC, Wright RS, Navarese EP, Lerch DM, Louie MJ, Lee LV, Letierce A, Robinson JG. Treatment effect of alirocumab according to age group, smoking status and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. J Clin Lipidol 2019;13:735-743. DOI: 10.1016/j.jacl.019.06.006.
26. Santos RD, Stein EA, Hovingh GK, Raal FJ, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol 2020;75:565-74. DOI: 10.1016/j.jacc2019.12.020.
27. **Raal FJ**, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman S, Huang F, Xue A, Albizem M, Scott R and Stein EA. Reduction in Lipoprotein(a) with PCSK9 Monoclonal Antibody Evolocumab (AMG 145). A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol 2014;63:1278-88.
28. **Raal FJ**, Guigliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Lipid Res 2016;57:1086-1096.
29. Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ. Effect of alirocumab on lipoprotein(a) over ≥ 1.5 years (from the Phase 3 ODYSSEY program). Am J Cardiol 2017;119:40-46.

30. **Raal FJ**, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020;382:1520-1530. DOI:10.1056/NEJMoa1913805.
31. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros MJ, Wijngaard PLJ, Kastelein JJP. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-1519. DOI:10.1056/NEJMoa12387.
32. Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 in homozygous familial hypercholesterolemia. The ORION-2 pilot study. Circulation 2020;141:1829-1831. DOI: 10.1161/CIRCULATIONAHA.119.044431.
33. Marais AD, Blom DJ, Raal FJ. Homozygous familial hypercholesterolemia and its treatment with inclisiran. Expert Opinion on Orphan Drugs. 2020;8(6):197-208. DOI:10.1080/21678707.2020.1784721.
34. **Raal FJ**, Chilton R, Ranjith N, et al. PCSK9 inhibitors: From nature's lessons to clinical utility. Endocrine, Metabolic & Immune Disorders – Drug Targets 2020;20:840-854. DOI: 10.2174/1871530320666200213114138.
35. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz G, Friedman A, Wijngaard PLJ, Conde LG, Kastelein JJP. Pooled patient-level analysis of Inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis . J Am Coll Cardiol 2021;77:1182-93. DOI:10.1016/j.jacc.2020.12.058.
36. Brandts J, Dharmayat KI, Vallejo-Vaz AJ, Sharabiani MTA, Jones R, Kastelein JJP, Raal FJ. Ray KK. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis 2021;325:46-56. DOI:10.1016/j.atherosclerosis.2021.03.042.

CHAPTER 5: ANGPTL3 INHIBITION

Despite high-intensity statin, ezetimibe, as well as PCSK9-inhibitor therapy, HoFH patients are unable to achieve acceptable LDL-C levels and often require LDL apheresis. As first author I recently published the results of a study with the ANGPTL3-inhibitor, evinacumab, in HoFH patients, also published in the *New England Journal of Medicine* (5; publication 1). This remarkable therapy which is given as a monthly intravenous infusion was shown to reduce LDL-C by a further 50% and the effect was independent of LDL receptor function so is equally effective in those HoFH patients with minimal or no residual LDL receptor function (null/null HoFH). For the first time the addition of this therapy will allow many of our HoFH patients to achieve near normal LDL-C levels. These novel therapies have reduced the need for lipoprotein apheresis or liver transplantation which is now only required for the most severe cases. Perhaps in the future, gene therapy for HoFH may also become a reality. Over the past three decades it has been heartwarming to witness how HoFH has been converted from a condition that was often fatal in childhood to a manageable dyslipidaemia which has extended the lives of these unfortunate patients and improved their quality of life (5; publication 2,3).

5. Publications

1. **Raal FJ**, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan K-C, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383:711-720. DOI: 10.1056/NEJMoa2004215.
2. Mohammed F, Seedat F, Raal FJ. Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes 2021;28:188-195.
3. Mohamed F, Botha TC, Raal FJ. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol 2021;32:213-218.

CHAPTER 6: FH IN SOUTH AFRICA

With my interest in FH spanning more than three decades, and in collaboration with many local, national and international colleagues, I have described the clinical presentation, genetics and prevalence of FH, both HeFH and HoFH, in all population groups in South Africa (6; publications 1-9). However, our knowledge about the prevalence of FH in black Africans remains rudimentary and requires further study, as very few black Africans have been diagnosed with FH and even less are being treated (6; publications 10-12). This is an important area of my ongoing and future research. Together with Hans-Georg Kraft and Gert Utermann, I was also the first to report high Lp(a) levels in patients with both HeFH and HoFH (6; publication 13).

6. Publications

1. Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, Van der Westhuyzen DR. Characterization of six patients who are double heterozygotes for familial hypercholesterolaemia and familial defective apo B-100. Arteriosclerosis and Thrombosis 1993;**13**:1076-1081.
2. Kotze MJ, Loubser O, Thiart R, de Villiers JNP, Langenhoven E, Theart L, Steyn K, Marais AD, Raal FJ. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet 1997;51:394-398.
3. Kotze MJ, de Villiers JNP, Loubser O, Thiart R, Scholtz CL, Raal FJ. A double mutant LDL receptor allele in a Cypriot family with heterozygous familial hypercholesterolaemia. Hum Genet 1997;100:101-103.
4. Thiart R, Loubser O, de Villiers JNP, Marx MP, Zaire R, Raal FJ, Kotze MJ. Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolaemia. Human Mutation 1998;1:S232-S233.
5. Callis M, Jansen S, Thiart R, de Villiers JN, Raal FJ, Kotze MJ. Mutation analysis in familial hypercholesterolaemia patients of different ancestries: identification of three novel LDLR gene mutations. Mol Cell Probes 1998;12:149-152.

6. Kotze MJ, Peeters AV, Loubser O, Theart L, du Plessis L, Hayes VM, de Jong G, de Villiers JN, Lombard CJ, Hansen PS, Raal FJ. Familial hypercholesterolaemia: potential diagnostic value of mutation screening in a paediatric population of South Africa. Clin Genet 1998;54:74-78.
7. Durst R, Colombo R, Shpitzen S, Avi LB, Raal FJ. Recent origin and spread of a common Lithuanian mutation, G197delLDLR, causing familial hypercholesterolemia: Positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. Am J Hum Genet 2001;68:1172-1188.
8. Marais AD, Kotze MJ, Raal FJ, Khine AA, Urban M, Talmud P, Humphries SE. Familial hypercholesterolaemia workshop for leveraging point of care testing and personalized medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc J Afr 2019;30:297-304. DOI: 10.5830/CVJA-2019-055.
9. **Raal FJ**, Bahassi EM, Turner TA, Stevens B. Stein EA. Cascade screening for Familial Hypercholesterolemia in South Africa: The Wits Find-FH Program. Atheroscler Thromb Vasc Biol 2020;40:2747-2755. DOI:10.1161/ATVBAHA.120.315040.
10. Ibe UK, Whittal R, Humphries SE, Pilcher G, Raal FJ. Analysis of mutations causing familial hypercholesterolaemia in native South African patients of different ancestry. S Afr Med J 2017;107:145-148.
11. Smyth N, Ramsay M, Raal FJ. Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. Curr Opin Lipidol 2018;29:72-79.
12. Hayat M, Kerr R, Bentley R, Rotimi CN, Raal FJ, Ramsay M. Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLOS One 15(2): e0229098. DOI: 10.1371/journal.pone.0229098.
13. Kraft H-G, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:522-528.

CHAPTER 7: LOCAL AND INTERNATIONAL FH AND LIPID GUIDELINES

I have been Chairperson and Secretary of the Society of Endocrinology, Metabolism and Diabetes of Southern Africa (SEMDSA) and have also been Secretary of the Lipid and Atherosclerosis Society of Southern Africa (LASSA) since its inception in 1989. In this capacity I have been intimately involved in the development and distribution of South African guidelines for the awareness and management of both FH as well as hyperlipidaemia in general (7; publications 1-15).

Progress in this area is not only important for our patients with HoFH and severe HeFH, but for all patients with FH, one of the commonest inherited disorders worldwide. In 2013, I acted on an expert panel to produce a paper which highlighted the extent to which FH is underdiagnosed and undertreated in the general population. We estimated that there are between 20 and 34 million individuals worldwide with FH and at least 120 000 individuals in South Africa (7; publication 16). As the condition is asymptomatic it is often missed and it is estimated that less than 5% individuals affected with HeFH are diagnosed worldwide. The article discussed recommendations on how to better diagnose and treat individuals and families with FH and to ultimately prevent premature coronary heart disease. This paper also highlighted the urgent worldwide need for diagnostic screening and timely and aggressive treatment of the condition in these high risk individuals. I have also co-authored Consensus Statements on the diagnosis and treatment of both HeFH and HoFH published in the European Heart Journal as well as other International FH guidelines. I have also been on the EAS Consensus Panel for Consensus Statements on statin associated muscle symptoms as well as the management of FH in children and adolescents (7; publications 16-27). I am on the Steering Committee developing a worldwide registry of HeFH and HoFH subjects which aims to assist with identification of undiagnosed FH subjects and to allow them to benefit from the remarkable novel therapies under development for this condition (7; publications 28-30). More recently, with the arrival of the coronavirus disease 2019 (COVID-19) pandemic, I have co-authored several manuscripts on the risk and importance of ongoing lipid-lowering therapy in FH patients who become infected with COVID-19 (7; publications 31,32).

I have also been asked to do several reviews on novel therapies for severe FH and continue to do so. This research, in which I have been intimately involved in both planning of study concepts and design, has been very rewarding to me and particularly to my FH patients. With these novel therapies in advanced stages of development, in which I have played a pivotal

role, it will be possible to effectively treat the hypercholesterolaemia in virtually all HeFH patients and a large percentage of HoFH patients. This will allow these patients to live healthier, longer lives.

7. Publications

1. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemias in South Africa – Clinical Guideline 2000. S Afr Med J 2000;90:164-178.
2. **Raal FJ**, Schamroth C, Klug E, Mills P. The South African Lipid Guidelines – Is there a need for an update? Cardiovasc J South Afr 2004;15:53-54.
3. Marais AD, Blom DJ, Raal FJ. Familial hypercholesterolaemia in South Africa: A reminder. S Afr Med J 2021;111:700-701 DOI:10.7196/SAMJ.2021.v111i8.15782.
4. **Raal FJ**, Marais AD, Schamroth C. Adoption of the European guidelines on cardiovascular disease prevention in clinical practice (based on De Baker et al. European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610) – Guide to lipid management. SA Heart, Suppl. July 2006; 12-16.
5. **Raal FJ**. Hypercholesterolaemia in children and young adults; current management. SA Fam Pract 2008;50(1):10-13.
6. Ramjeeth A, Butkow N, Raal F, Maholwana-Mokgatlhe M. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: The South African Not At Goal study (SA-NAG). Cardiovasc J Afr 2008:19:88-94.
7. **Raal F**, Schamroth C, Blom D et al. CEPHEUS SA: A South African survey on the under-treatment of hypercholesterolaemia. Cardiovasc J Afr 2011;22:234-240.
8. South African Dyslipidaemia Guideline Consensus Statement. A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J 2012;102:177-188.

9. Klug EQ, Raal FJ, Marais AD, Taskinen M-R, Dalby AJ, Schamroth C, Rappaport N, Jankelow D, Blom DJ, Catsicas R, Webb DA. South African Dyslipidaemia Guideline Consensus Statement. S Afr Fam Pract 2013;55(1):9-18.
10. **Raal FJ**, Blom DJ, Naidoo S, Bramlage P, Brudi P. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovasc J Afr 2013;24(8):330-338.
11. Klug EQ, Raal FJ. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J 2020;110(11)1059. DOI:10.7196/SAMJ.2020.v110i11.1519.
12. Chiang C, Ferrieres J, Gotcheva NN, Raal FJ, Shehab A, Sung J, Henriksson KM, Hermans MP. Suboptimal control of lipid levels: Results from 29 countries participating in the Centralized Pan-Regional Surveys on the Under treatment of Hypercholesterolemia (CEPHEUS). Journal of Atherosclerosis and Thrombosis 2016;23:567-587.
13. Klug E, Raal FJ, Marais AD, Smuts CM, Schamroth C, Jankelow D, Blom DJ, Webb DA. South African Dyslipidaemia Guideline Consensus Statement 2018. S Afr Med J 2018;11(2):973-997.
14. Blom DJ, Ranjith N, Joshi P, Naidoo P, van Tonder A, Musa MG, Leisegang R, Trokis JS, Makan H, Raal FJ. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr 2020;31:245-251. DOI:10.5830/CVJA-2020-010.
15. Blom DJ, Raal F, Amod A, Naidoo P, Lai Y. Management of low-density lipoprotein cholesterol levels in South Africa: The International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr 2019;30:15-23. DOI: 10.5830/CVJA-2018-054.
16. Nordestgaard BG, Chapman MS, Raal FJ et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. European Heart Journal 2013;34:3478-3490.
17. **Raal FJ** and Santos RD. Homozygous familial hypercholesterolaemia: Current perspectives on diagnosis and treatment. Atherosclerosis 2012;223:262-268.
18. Stein EA, Raal FJ. Polygenic familial hypercholesterolaemia: does it matter? Editorial Lancet 2013;381:1255-57.

19. Watts GF, Gidding S, Wierzbicki AS, Toth P, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJG, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S and Kastelein JJP. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology 2014;171:309-325.
20. **Raal FJ** and Stein EA. What matters most in pediatric familial hypercholesterolemia, genotype or phenotype? Journal of Lipid Research 2014;55:947-955.
21. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts, GF, Averna M, Boileau C, Boren J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AFH, Stroes E, Taskinen M, Wiegman A, Wiklund O and Chapman MJ. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal 2014;35:2146-57.
22. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Raal FJ, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36:2425-2437.
23. Gidding SS, Champagne MA, De Ferranti SD, Raal FJ, et al. The agenda for Familial Hypercholesterolemia. A Scientific Statement from the American Heart Association. Circulation 2015;132:2167-2192.
24. Ference BA, Ginsberg HN, Graham I, Raal FJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017;38:2459-2472.
25. **Raal FJ**, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis 2018;277:483-492.

26. Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon J, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard GB, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal F, Ray KK, Schunkert H, Taskinen M-R, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-2330. DOI: 10.1093/eurheartj/ehz962.
27. Watts GF, Gidding SS, Mata P, Raal FJ, et al. Familial hypercholesterolemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol 2020;17(6):360-377. DOI:10.1038/s41569-019-0325-8.
28. Vallejo-Vaz, AJ, Seshasai SR, Cole D, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, et al. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis 2015;243:257-59.
29. The EAS Familial Hypercholesterolaemia Studies Collaboration. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS familial hypercholesterolaemia studies collaboration Atherosclerosis Suppl. 2016;22:1-32.
30. EAS Familial Hypercholesterolaemia Studies Collaboration. Overview of the current status of and initiatives related to familial hypercholesterolaemia in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018;277:234-255.
31. Vuorio A, Raal FJ, Kaste M, Kovanen PT. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment Atherosclerosis 2021;320:53-60. DOI:10.1016/j.atherosclerosis.2021.01.021.
32. Vuorio A, Raal F, Kovanen PT. Hospitalized children with familial hypercholesterolemia and COVID-19: a case for preventative anticoagulation. Frontiers in Cardiovascular Medicine 8:657719. DOI:10.3389/fcvm.2021.657719.

CHAPTER 8: REDUCTION IN MORTALITY IN SEVERE FH

Prior to statins HoFH patients rarely survived beyond the age of 20 years. The pivotal high dose statin studies we conducted with simvastatin, atorvastatin and rosuvastatin confirmed the efficacy of high intensity statin therapy in this patient group. Although ideal LDL-C levels are not achieved with the use of high dose statins, cardiovascular morbidity and mortality have definitely been reduced and life expectancy has been prolonged (8; publications 1-4). I was the first to describe the long-term cardiovascular benefit of lipid-lowering therapy in the largest cohort of HoFH patients reported at the time (8; publication 1). With the newer therapies and novel therapies under development hopefully morbidity and mortality from FH will be reduced even further.

8. Publications

1. **Raal FJ**, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-2207.
2. **Raal FJ**, Sjouke B, Hovingh GK, Isaac BF. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis 2016;248:238-44.
3. **Raal FJ**, Sjouke B, Hovingh GK, Isaac BF. Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. Data in Brief 2016;7:1458-62.
4. Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. European Heart Journal 2018;39:1162-1168.

CHAPTER 9: CONCLUSIONS AND PLANNED FUTURE RESEARCH

A major focus of my research remains the clinical, biochemical, genetic and therapeutic management of FH. I continue to conduct studies with novel therapies such as the adnectin LIB003, a novel PCSK9-inhibitor therapy, as well as ANGPTL3-inhibitor therapy, evinacumab, in this patient group. These therapies have had a major impact on the lives of FH patients, particularly those with HoFH. It has been a wonderful experience for me to observe my HoFH patients, many of whom I have been treating from a very young age and for over 30 years, mature and grow up. It has been very rewarding to observe their gratitude and their joy as their LDL-C levels have been lowered further and further with these novel therapies.

Over the forthcoming years I plan to build on my research, individually and together with my national and international collaborators, to develop novel and exciting projects that have emanated from my current research work.

One area of future research is to prioritize the identification of FH in our black African population. Following a generous donation from Evan Stein, a Wits graduate, the *Evan Stein Centre for Familial Hypercholesterolaemia* was established at the University of the Witwatersrand in 2015 to assist with the identification and treatment of people with FH in South Africa. To date over 1000 FH patients and their family members have been screened. The project will continue until at least 2023 and a priority is to identify more black African subjects with FH as we know very little about the prevalence of FH in this population group. With a population of over 40 million, there should be approximately 130 000 black Africans with FH in South Africa alone, but very few have been identified and very few are receiving lipid lowering medication. This is therefore a very important area of future research. I have two postgraduates involved in research in this area. Natalie Smyth is investigating next generation sequencing of black African subjects with both low and high LDL-C levels in order to try to identify both LDL-C lowering and LDL-C raising variants in this population group. Dr Reinhardt Hesse will be using machine learning on biochemical data, based on laboratory lipid profiles, for the prediction of mutation presence in suspected FH cases. Another area of interest is Lp(a), an independent risk factor for atherosclerotic cardiovascular disease. Whether Lp(a) contributes to atherosclerotic cardiovascular disease in the black African population remains unknown.

My international collaboration and networking will continue and will hopefully expand so that I can continue to contribute to international clinical research in the field of lipidology and atherosclerosis, particularly in the field of familial hypercholesterolaemia, the most common inherited disease in man.